Development of Extended-Release Formulations Containing Cyclobenzaprine Based on Physiologically Based Biopharmaceutics Modeling and Bioequivalence Safe Space.

MLA

Miranda dos Santos, Everton, et al. “Development of Extended-Release Formulations Containing Cyclobenzaprine Based on Physiologically Based Biopharmaceutics Modeling and Bioequivalence Safe Space.” Journal of Pharmaceutical Sciences, vol. 112, no. 12, Dec. 2023, pp. 3131–40. EBSCOhost, https://doi.org/10.1016/j.xphs.2023.07.012.

APA

Miranda dos Santos, E., Ferraz, H. G., Issa, M. G., & Duque, M. D. (2023). Development of Extended-Release Formulations Containing Cyclobenzaprine Based on Physiologically Based Biopharmaceutics Modeling and Bioequivalence Safe Space. Journal of Pharmaceutical Sciences, 112(12), 3131–3140. https://doi.org/10.1016/j.xphs.2023.07.012

Chicago

Miranda dos Santos, Everton, Humberto Gomes Ferraz, Michele Georges Issa, and Marcelo Dutra Duque. 2023. “Development of Extended-Release Formulations Containing Cyclobenzaprine Based on Physiologically Based Biopharmaceutics Modeling and Bioequivalence Safe Space.” Journal of Pharmaceutical Sciences 112 (12): 3131–40. doi:10.1016/j.xphs.2023.07.012.